It seems to me (DCTH)' shares not be R/S= why shares will move higher , on other side III test pass FDA and selling already in Europe - I believe that market and day traders will analyse 'Delcath Systems, Inc. (DCTH)' and will find out that shares worth more then $25 dollars a share when a news regarding that fact that read below =
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC) in the Fall of 2017. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.
In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
Best Analyses re"(DCTH) June 20, 2017
So far we’ve looked at the technical indicators that showcase the immediate and historical movement of the stock. Now it’s time to look at things over a longer time span. DCTH’s +0.07 has offered up a rich set of data upon which traders can base their expectations and indeed, their actions. Based on the reading, an overall sentiment has emerged and this can be said to be positive. A big reason for this has been the historical performance of the stock. Taken over a much broader base of measurement, DCTH has actually underperformed the S&P 500 by -114.01. This performance has created the perfect environment and now the stock has higher volatility levels compared to other companies in the same sector. To say that these readings and the inherent performance of the stock has placed it on the radar of many traders and analysts would indeed be an understatement. Interestingly enough, other factors are also playing their part in bolstering sentiments. This is especially so when you look at DCTH’s 406.14%. DCTH has an ATR reading of 25, suggesting much of what has already been established by the other technical factors. DCTH has made it very easy for traders to make up their minds; these are data sets that don’t get any clearer or compelling.
The mind is like a parachute it works best when it is open
